Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
– Sell
-348
Closed -$47K – 1070
2022
Q3
$47K Buy
348
+12
+4% +$1.72K ﹤0.01% 1009
2022
Q2
$51K Buy
+336
New +$51.3K ﹤0.01% 1072

Other funds holding ABBV

Natixis's ABBV Position: Q3 2026 in Review

Natixis reduced its AbbVie (ABBV) stake by 3.1% in Q3 2026, selling an estimated $2.09M and leaving 258,897 shares worth $67.7M. The position accounts for 0.24% of the portfolio, ranked #50.

Natixis first reported a position in ABBV in Q2 2013 and has held it in 51 quarters since. The position peaked at $199M in Q3 2018. 4,285 funds tracked by Wall St. Rank hold ABBV as of Q3 2026.

  • Natixis held 258,897 shares of AbbVie worth $67.7M as of Q3 2026.
  • Natixis sold 8,158 AbbVie shares in Q3 2026, an estimated $2.09M.
  • AbbVie made up 0.24% of Natixis's portfolio in Q3 2026, its #50 holding.
  • Natixis first reported a position in AbbVie in Q2 2013 and has held it in 51 quarters since.
  • Natixis's AbbVie position peaked at $199M in Q3 2018.
  • 4,285 funds tracked by Wall St. Rank held AbbVie as of Q3 2026.

Based on Natixis's 13F filing for Q3 2026, filed 6 Nov 2026.